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COMMUNITY-ACQUIRED PNEUMONIA 

What is new in aetiology and treatment 

Stephen Monifort, Frederick F. F enech 
Community-acquired pneumonia (CAP) 
remains a considerable problem in terms 
of morbidity, mortality and use of hospital 
resources despite the remarkable advances 
in antibiotic therapy. It is estimated that 
in the u.K. 1 per HXX> in the general 
population is admitted with pneumonia 
annually (1) and pneumonia xcounts for 
about 10 times as many deaths (in U.K.) 
as all other infections combined (1). The 
mortality in published series has ranged 
from 6.7 - 18% in the British series (1) and 
6-24% in the U.S.A, (1). These 
percentages change according to the 
organism causing the pneumonia and the 
age of the patient The past 20 years have 
been marked by striking changes in the 
pattern of pneumonias, a<; manifested by 
new diseases, new modes of transmission 
and new manifestations of old diseases. 
In Malta IDeumonia is also a common 
cause of hospital admission and we are at 
the moment carrying out a study to 
determine the frequency and the clinical 
pattern of the disease loca1Iy. Hospital 
cases are however only part of the total 
incidence of CAP as many cases are 
treated at home and never reach hospital. 
In fxt the incidence of CAP is unknown 
but estimates vary between 1-10 per 1(XX) 
of the population, (2,3) 
In the evaluation of a patient with 
pneumonia, the usual histo- pathological 
cla<;sification is of little value to the 
clinician. Indeed, having made the 
diagnosis, the major consideration is to 
interpret the clinical setting in which the 
pneumonia occurs in order to infer from 
this the most likely aetiological diagnosis, 
To do this one has to have some idea of 
common aetiological agents in the 
community as well as determine the 
condition of the host and the environment 
in which the pneumonia develops. 
Table 1 (1-7) summarises the aetiological 
frequencies of CAP in various studies 
reported over a 15 year period. There 
is a high incidence of unidentified 
causative micro organisms, probably due 
to antibiotics given prior to hospital 
admission, masking the infective 
organisms when sputum culture is 
attempted. In fact when other tests like 
counter immuno-electrophoresis (CIE) 
were carried out, (5), only in 2 to 4% of 
cases was the causative organism 
undetected. Strep. pneumonia was still 
the most common cause in almost all the 
series even though there was an increasing 
incidence of viral and mycoplasmal 
pncumonias, Mycoplasma, which Ixks a 
cell wall, occurs usually in epidemics 
which occur at intervals of 4-5 years. 
LegionelIa pneumophilia is also 
increasing in frequency. It is therefore 
important to monitor the pattern of 
aetiologies of pneumonias at regular 
intervals, as the frequency of various 
agents changes over the years. In a study 
from Yale (8), the changing pattern of 
causes of pneumonia between 1%9 to 
1972 and 1979 to 1982 were comJXlfed. 
Table 2 showed that there was a decrease 
in bacterial causes from 63% to 48% as 
well as an increase in fungal and viral 
causes, These changes in incidence reflect 
changes in the pattern of medical practice 
over the years where there is an increase 
in patients with some degree of 
immunosuppression either because of the 
nature of the disease or as part of the 
therapy (9). 
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TABLE 1 AETIOLOGIES OF COMMUNfTY-ACOUIRED PNEUMONIA 1971-1987 

Author No of % % Viral or % % % % % % 

Patients Unknown Mycoplasma S Pneum. S Aureus H Inftu. Gram Neg .Legionella OTHER 
FEKETY 100 29 5 62 2 
1971 
SULLlVAN 292 36 7 35 6 5 11 
1972 
WHITE 210 52 29 11 4 2 1.5 1.5 4 
1981 
MACFARLANE 127 2.4 11 76 2.4 3 0.8 15 5.5 
1982 
McNABB 80 36 6.25 56 3.75 6.25 1.25 1.25 3.25 
1984 
MARRIE 301 34 20.3 8.6 4.6 6.3 2 3.9 20 
1987 
BTC STUDY 453 33 25 34 6 2 7 
1987 
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TABLE 2 INFECTIOUS PNEUMONIAS IN HOSPITALISED PATIENTS: 

THE CHANGING SPECTRUM AT THE YALE NEW HAVEN MEDICAL CENTRE 

Pathogenic Agents July 1969 to July 1979 to 
Isolated Jan.1972 (%) Jan. 1982 (%) 
Total bacterial causes 63.8% 48.6% 
Tolal fungal 7.2% 13.2% 
Total viral 17.5% 32.9% 
Total Patients Reviewed 935 1,175 
(FICK R.B. et, THE AMERICA JOURNAL OF MEDICINE, 1983, 74,2) 
TABLE 3 CATEGORIES OF PATIENTS WITH PNEUMONIA 
TYPE I - PNEUMONIA IN A PREVIOUSLY HEALTHY PATIENT 
TYPE 11 - PNEUMONIA IN PREVIOUSLY UNHEALTHY LUNGS 
TYPE III - POST-INFLUENZAL PNEUMONIA 
TYPE IV - PNEUMONIA IN A COMPROMISED PATIENT 
TYPE V HOSPITAL ACQUIRED PNEUMONIA 
Table 3 shows the categories of patients in 
which different types of pneumonias occur 
in various groups of patients. This is 
helpful as it can give a good indication as 
to the likely aetiological causes of the 
pneumonia. The main causative agent'> of 
severe pneumonia in previously healthy 
patients, are likely to be either 
pneumococcal, mycoplasmal or viral. 
Table 4 Though the real prevalence of 
pneumococcal pneumonia in hospital 
practice is difficult to determine, becauscof 
pre-admission antibiotic therapy, it should 
still be considered as the most common 
cause of CAP in a previously healthy 
subjccL It is worrying to note that thereare 
emerging reports of pneumococci which 
are penicillin resistant (10) especially in 
South Africa and New Guinea where 
penicillin prophylaxis used to be given 
because of pneumococcal epidemics (11). 
In the last 15 years Legionella and a 
member of the Ol1amydia genus known as 
TWAR have also emerged as potential 
pathogens in this type of patient (12). A 
dramatic outbreak of pneumonia (182 cases 
with 29 deaths) in a Philadelphia 
Legionnaires convention in July 1976 led 
to the identification of a unique, fastidious, 
Gram-ve, aerobic, intracellular bacillus 
the following January. Retrospective 
studies identified this organism in cases 
of pneumonia occurring 25 years earlier. 
The commonest species (24 in all) is 
Legionella pneumophila and this has 12 
subgroups. The incidence of 
Legionnaires' disease in various series of 
CAP ranges from 1-27%. In Malta there 
were some imported cases of 
Legionnaires' disease some of whom 
died. One case was in a man who had not 
gone abroad but the local source was not 
identified. Maltese sources are becoming 
more likely with the increasing use of 
air-conditioners. Legionella produces a 
lobar pneumonia or bronchopneumonia 
and can show CXR progression whilst 
the patient is on treatmenL 
An important feature is the lack of purulent 
sputum in the prc,,<;ence of a consolidation. 
Extrapulmonary involvement ranging 
from diarrhoea to changes in mental status 
may be seen in 25-75% of patients. All 
environmental sources of the organism 
are related to water and include cooling 
towers, condensers, humidifiers, air­
conditioners, ncbulizers filled with tap 
water, aerosols created by showers or 
water fauccts. The primary method of 
environmental control has been 10 inerease 
water temperature and chlorination. The 
early administration of erythromycin (4g1 
day IV for at least 3 weeks) _+ Rifampicin 
is most important as the overJ.l1 case 
fatality is 5-25% in previously healthy 
patients and up to 80% in 
immunocompromised patient'> (12). 
A newly described Chlamydia organism 
called 1WAR wa.<; shown 10 be the cause 
of 6% of pneumonias in 301 patient'> 
admitted to a Nova Scotia Hospital 
between 1981 and 1984 (7). It was the 
third most common cause in this study by 
Marrie, causing a mild pneumonia in 
teenagers; In patients with a pre-existing 
chronic lung condition, it can produce a 
severe illness. Its name is derived from 
the laboratory designation of the fIrst two 
isolates TW183 and AR39. It is distinct 
from C. trachomatis and C. psittaci and 
the drug of choice for its treatment is 
erythromycin. The diagnosis is made 
through micro- immunofluorescence 
using 1WAR as antigen. 
Patients with previously unhealthy lungs 
are susceptible to a different spectrum of 
organisms causing their pneumonias 
(Table 5). Pneumococcus together with 
Haemophilus influenzae is still the 
commonest organism causing pneumonia 
in chronic bronchi tics and in patients with 
non-cystic fibrosis bronchiectasis, while 
TABLE 4 LIKELY AETIOLOGICAL AGENTS OF PNEUMONIA IN PREVIOUSLY 
HEALTHY PATIENTS 
VIRUSES 	 INFLUENZA ADENO-VIRUS 
BACTERIA 	 PNEUMOCOCCUS 
LEGIONELLA 
MYCOPLASMA 
CHLAMYDIA, PSITIACI, lWAR 
COXIELLA BURNETI 
MYCO. TUBERCU.OSIS: RARE BUT LETHAL, HGHLY TREATABLE 
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Finally the following therapeutic regimes TABLE 5 LIKELY AETKJLOGICAL AGENTS OF PNEUMONIA IN PATIENTS WrrH 
are suggested for the various types ofPREVIOUSLY UNHEALTHY LUNGS 
CAP. In patients who were previously 
healthy Erthromycin is a good choice asCOPD PATIENTS - PNEUMOCOCCUS 
AND NON-CYSTIC 	 HAEMOPHILUS all the common microorganisms involved 
FIBROSIS 	 BRANHAMELLA CATARRHALlS I including the potentially lethal Legionel\a 
BRONCHIECTASIS MYCOPLASMA 	 I are senslUve to it When resistance is 
VIRUSES 	 I encountered amoxicillin or tetracycline 
are good alternatives. (Table 8). 
CYSTIC FIBROSIS - PSEUDOtv1ONAS a 
PATIENTS 	 STAPHYLOCOCCUS au. 
In patients with previously unhealthy
TABLE 6 COMMUNITY ACQUIRED PNEUMONIA IN IMMUNOSUPPRESSED lungs a different group of antibiotics 
PATIENTS (Table lOP) are suggested. a'> most of the 
organisms responsible are resistant to 
- PNEUMOCYSTIS C. 
erythromycin. A new and important 
- VIRAL ESPECIALLY CMV 
antibiotic group in this context are the 4­
- FUNGI 	 - CRYPTOCOCCUS 
amino Quinoiones which are derivatives 
- CANDIDA 
of nalidixic acid. They are rapidly
- NOCARDIA bactericidal acting on DNA gyrase (an
- ZYGOMYCETES 
enzyme which manipulates bacterial DNA 
so a'> to be able to be 'packCcl' in the small 
- BACTERIA - GRAM-VE BACILLI bacterium); they have excellent WBC 
- STAPH. AUREUS 
and tissue compartment penetration and 
- MYCOBACTERIA have good bin-availability when given 
Pseudomonas and Staph. aureus are the The immccliate institution of treatment or<llly. There are no naturally occurring 
commonest micro-organisms in cystic with the most appropriate antibiotics is quino\ases and so resistance is very 
fibrosis patienL'>. vital if the prognosis is to be improvccl. In unlikely to occur quickly if at all. 
a 90- centre study with 450 patients (1) Ciprotloxacin is the best quinolone a'> 
Br.mhmnella catarrhalis used to he thought with CAP, there were no deaths in patienL'> regard,> the respiratory system (14) and 
of <L'> just a commensal but is being who received antibiotics before has a very wicle spectrum when compared 
inerca..,ingly rccob'l1isccl as a cause of lower hospiuliisation. It was also found that to other antibiotics. Sputum levels of 
respimtory trdct infcx;tion in this group of certain features predicted a worse ciprof1oxacin arc in the order of 70% of 
patienL'>. Thi.., is a Gmm-negative, aerobic prognosis in patienL'> with pneumonia. scrwn levels and even higher in lung 
diplococcus. TIle majority (50-70%) of (Table 7). Not all these features will be parenchyma greatly exeeecling the M.i.C. 
stmins produce B-lactmna<;es and arc thus present in the same patient but the presence of important respiratory pathogens. 
resisumt to penicillins but sensitive to of any of them should alert the physician Overall efficacy in chest infcx;tions is 
erythromycin, tetracycline or to hmpitalise the patient urgently. over 90%. Its empilical use in CAP 
ciprofloxacin (13). In post-influenzal 
TABLE 7 CLINICAL FEATURES ASSOCIATED WrrH INCREASED MORTALrrY Ipneumonias, onc must never forget iL, 
<L'>-'>ociation with SUlpho aureus, but again 
1. AGE > 60 yearspneumex;occus is the commonest cause 2. RESPIRATORY RATE > 3D/min.
of pneumonia in these patienL'>. 3. DIASTOLlC B.P. < 60 mm.Hg 
4. CYANOSIS 
The number of immunosuppressed 5. MENTAL CONFUSION 
patienL, in the community today has 6. LOW Pa02 < 8 KPa 
increased because of drugs such as 7. VERY LOW OR VERY HIGH WBC COUNT 
steroici'i, organ trdm;plants, and clisc<lSCs 
with disturbed immunity - the best known TABLE 8 ANTIBIOTIC REGIME FOR COMMUNITY ACQUIRED PNEUMONIA IN 
being the acquired immunodeficiency A HEALTHY HOST 
syndrome (AIDS). Such pneumonias 
require urgent attention ,L, they carry a - PNEUMOCOCCUS 
worse Prob'l10Sls. 
- LEGIONELLA 	 ALL SENSITIVE TO 
ERYTHROMYCINThe aetiological agenL,> in these patienL, 
- MYCOPLASMA
constitute a different spectrum of micro­
organisms, fungi, viruses and protozoa a'> 
- CHLAMYDIA 
causes of pneumonia. Gram-ve bacilli, 
staph. aurcus and mycobacteria especially 
- OTHER SUGGESTED ANTIBIOTICS IF MICRO-CRGANISM IS 
the atypical ones constitute the majority RESISTANT 
of the bacteria causing such infections. TETRACYCLINE 
(Table 6). AMOXICILLlN 
- -
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(especially in patients with previously 
healthy lungs) is inadvisable in view of 
the ready availability of suitable 
alternatives, as well as the relatively poor 
susceptibility of pneumococcus. 
Aucloxacillin or amoxycillin + clavulinic 
acid are usually given in post-influenza! 
pneumonia due to the possibility of Staph. 
pneumonia Ciprofloxacin can also be 
used. 
In Pneumonias in immunosuppressed 
patients treatment must start treatment 
empirically without delay and changed if 
necessary according ID sensitivity results. 
Admission to hospital in such cases is 
mandatory. Table 10 shows 
recommendations of antibiotics regimes 
in immunosuppressed patients. These 
recommendations were modified from 
one by Masur (15). 
IN CONCLUSION, 
- Act fast in treating suspected pneumonia 
Though Strep.pneumonia is still the 
commonest cause, think of newer agents 
and consider host and environment in 
which pneumonia developed. 
- Though Erythromycin is still the first 
line drug, newer agents may be indicated. 
- Refer to hospital immunocompromised 
patients with clinical features of 
pneumonia. 
TABLE 9 ANTIBIOTIC REGIME FOR 
COMMUNITY ACQUIRED 
PNEUMONIA IN PATIENTS WITH 
PREVIOUSLY UNHEALTHY LUNGS 
AMOXICILLlN 
CLAVULANATE 
POTENTIATED AMOXCILLlN 
CIPROFLOXACIN 
CO-TRIMAXAZOLE 
CEPHALOSPORIN + 
AMINOGLYCOSIDE IN THE 
HOSPITAL ENVIRONMENT 
TABLE 10 RATlONAL ANTIMICROBIAL THERAPEUTlC REGIMENS 

FOR IMMUNOSUPPRESSED PATIENTS WITH EXTENSIVE PNEUMONIAS 

REGIMEN 	 SUSPECTED PATHOGENS LIKELY 

TO BE ADEOUATELY TREATED 

CO-TRIMOXAZOLE (high dose) 

OR 

TRIMETHOPRIM + DAPSONE PNEUMOCYSTIS C. 

OR 

PENTAMIDINE IV OR NEBULlZED 

ERYTHROMYCIN LEGIONELLA, MYCOPLASMA 

DHPG (ganciclovir) 	 CMV 
QUADRUPLE THERAPY 	 MYCOBACTERIA 
AMPHOTERICIN 	 FUNGAL INFECTION 
CEPHALOSPORIN 	 AEROBIC GRAM + ve COCCI 
AMINOGLYCOSIDE 	 AEROBIC GRAM - ve COCCI 
MODIFIED FROM MASUR et ai, JAMA. MARCH 22129. VOL. 253 NO.12. 
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